Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Liquid biopsy company Angle said the University Medical Centre Hamburg-Eppendorf had published results of work demonstrating that its technology could be used to investigate the effectiveness of immunotherapy drugs to treat lung cancer.
'Immunotherapy drugs can be very effective for some patients,' Angle said.
'However, typically only 20-30% of patients will respond and it is crucial to be able to accurately identify which patients, both to reduce the patient's exposure to unnecessary drug toxicity and to reduce unnecessary healthcare expenditure.'
The university's research was undertaken using Parsortix over a three year period and published in Cancers, a peer-reviewed medical journal.
It showed that in a head-to-head comparison of 97 lung cancer patients, Parsortix was able to detect circulating tumor cells in nearly twice as many patients as the leading competing system.
Furthermore, the research showed that the PD-L1 expression in a tissue biopsy did not always reflect the heterogeneity of PD-L1 expression in the cancer of patients with multiple tumor sites.
A Parsortix CTC liquid biopsy could therefore provide more comprehensive information, Angle said.
At 2:51pm: (LON:AGL) Angle PLC share price was +2.3p at 59p